The hematopoietic stem cell transplant (HPSCT) market is expected to grow with a substantial CAGR over the forecast period, i.e., 2021 – 2029. The increasing prevalence of hematopoietic disorders and the high success rate of transplants are the major factors that are expected to boost the growth of the market. As per our analysis, more than 129,000 people in the United States are evaluated to be diagnosed with a serious blood disorder in 2021. Apart from that, the rise in the ageing population across the globe is also a significant contributor to the growth of this market. According to the United Nations Organisation, by the end of 2050, every 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019. Furthermore, with advancements in lifesaving technologies, the global hematopoietic stem cell transplant market size is projected to witness a rapid and steady expansion over the forecast period.
On the basis of transplant type, the market is segmented into allogeneic and autologous segments. The allogeneic transplant type segment is estimated to hold the largest market share in 2021 and is expected to continue this trend throughout the forecast period. Allogeneic stem cell transplantation involves the process of transfer of stem cells from a donor other than the patient. One of the major benefits of this process is that the patient who has undergone the transplantation process creates a new immune system after the donated cells are engrafted into the patient’s body. However, the demand for autologous transplants is expected to grow significantly during the forecast period on account of the lack of availability of donors for allogeneic transplantation. By application, the bone marrow transplant segment is anticipated to grow with a significant CAGR on the back of growing R&D in the field of healthcare and the vast variety of diseases treated by this procedure. CLICK TO DOWNLOAD SAMPLE REPORT
On the basis of geographical analysis, the global hematopoietic stem cell transplant market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The North American hematopoietic stem cell transplant market is anticipated to grab the leading position in terms of market share by the end of 2021 as a result of the rising demand for better treatment options and the increasing occurrence of leukemia and lymphoma. The data from National Cancer Institute depicts that the estimated number of new cases of leukemia in the United States in 2020 was 60,530, which accounts for about 3.4% of all the new cancer cases. Apart from these, the market growth in this region can also be attributed to the high investments in research and development for developing effective treatment for hematopoietic disorders. On the other hand, the market in Europe is also anticipated to grab a considerable share in the market owing to the overall increase in the success rate of transplants, a technologically advanced healthcare system, and a high-income population.
The global hematopoietic stem cell transplant market is further classified on the basis of region as follows:
Our in-depth analysis of the global hematopoietic stem cell transplant market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Increasing number of incidences of luekemia and lymphoma is a crucial factor driving market growth.
The market is anticipated to attain a substantial CAGR over the forecast period, i.e., 2021-2029.
High cost of transplantation is the major factor estimated to hamper the market growth.
The market in North America is anticipated to provide the highest business growth opportunities for the market on the back of growing demand for improved treatment.
The major players in the market are Lonza Group Ltd., Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by transplant type, application, disease indication, end user, and by region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization